Intermodal Freight Transportation Market Size, Share & Trends Analysis Report By Type (Road-rail, Road-water, Road-air), By Operation, By Services (Fleet Management, Intermodal Terminals), By End Use, By Region, And Segment Forecasts, 2024 - 2030
Market Size & Trends
The global intermodal freight transportation market size was estimated at USD 42.91 billion in 2023 and is expected to register a CAGR of 12.1% from 2024 to 2030.Intermodal freight transportation is the movement of goods using multiple modes of transportation (such as trucks, trains, and ships) in a single journey, without handling the freight itself when changing modes. The market is growing significantly due to the need for a more reliable, safe, efficient transportation system, containerization permitting easy handling of goods, growth in the domestic intermodal transportation market, and free trade agreements.
The intermodal freight transportation market emphasizes the need for a more reliable transportation system due to the increasing demand for timely and secure delivery of goods. Reliability in transportation ensures that goods arrive at their destination without damage, reducing losses and improving customer satisfaction. Safety is a paramount concern, particularly when transporting hazardous materials, necessitating robust safety protocols and infrastructure. Efficient transportation systems reduce transit times and operational costs, enhancing overall supply chain efficiency. Technological advancements such as real-time tracking and predictive analytics contribute significantly to improving the reliability and efficiency of intermodal transportation. Investments in infrastructure, such as modernizing ports and railways, are critical to meeting these demands and supporting market growth.
Containerization revolutionizes the handling of goods by standardizing cargo units, which simplifies loading, unloading, and transfer processes across different transportation modes. This standardization allows for seamless integration between ships, trucks, and trains, reducing the risk of damage and loss during transit. The use of containers enhances security by minimizing the need for manual handling and providing robust, tamper-proof units. Containers also optimize space utilization, allowing for efficient stacking and storage, which maximizes cargo services and reduces transportation costs. The versatility of containers enables them to carry a wide range of goods, including perishable items and hazardous materials, making them essential in the global supply chain. Overall, containerization significantly enhances the efficiency and reliability of the intermodal freight transportation system.
The domestic intermodal transportation market is experiencing significant growth due to the increasing demand for efficient, and cost-effective transportation solutions. This growth is driven by the rising volume of e-commerce and the need for faster delivery times to meet consumer expectations. Intermodal transportation offers a competitive advantage by combining the strengths of different transport modes, such as the flexibility of trucks and the cost-efficiency of rail. Environmental concerns also play a role, as intermodal solutions typically have a lower carbon footprint than traditional road transport alone. Infrastructure investments, such as the expansion of rail networks and the modernization of ports, further support the growth of the domestic intermodal market. Additionally, government policies and incentives aimed at promoting intermodal transportation contribute to its increasing adoption and market expansion.
Free trade agreements (FTAs) significantly impact the intermodal freight transportation market by facilitating the seamless movement of goods across borders. FTAs reduce or eliminate tariffs and trade barriers, making it more cost-effective for businesses to engage in international trade. These agreements encourage economic cooperation and integration, leading to increased trade volumes and the need for efficient transportation solutions. The market benefits from FTAs as they streamline customs procedures, reducing delays and enhancing the predictability of transit times. Additionally, FTAs promote investment in transportation infrastructure, such as ports and railways, to support the growing trade demands.
Global Intermodal Freight Transportation Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global intermodal freight transportation Market report based on type, operation, services, end use, and region.
- Type Outlook (Revenue, USD Million, 2017 - 2030)
- Road-rail
- Road-water
- Road-air
- Others
- Operation Outlook (Revenue, USD Million, 2017 - 2030)
- Domestic Intermodal
- International Intermodal
- Services Outlook (Revenue, USD Million, 2017 - 2030)
- Fleet Management
- Intermodal Terminals
- Transportation & Warehousing Services
- Freight Routing & Scheduling
- Others
- End Use Outlook (Revenue, USD Million, 2017 - 2030)
- Automotive
- Aerospace and Defense
- Healthcare
- Energy & Utilities
- Food & Beverage
- Construction
- Others
- Regional Outlook (Revenue, USD Million, 2017 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Middle East and Africa (MEA)
- KSA
- UAE
- South Africa
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Regional Scope
- 1.1.2. Estimates and Forecast Timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR’s Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
- 1.4. Information or Data Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Validation
- 1.5.1. Region Wise Market: Base Estimates
- 1.5.2. Global Market: CAGR Calculation
- 1.6. Model Details
- 1.6.1. Commodity Flow Analysis (Model 1)
- 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
- 1.6.3. QFD Model Sizing & Forecasting (Model 3)
- 1.6.4. Bottom-Up Approach (Model 4)
- 1.7. Market Definitions
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Sterile Injectables CDMO Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Pipeline and Approvals of Injectables
- 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
- 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
- 3.2.1.4. Increasing Demand for Cell & Gene Therapies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
- 3.2.2.2. Challenges Related to Quality Control
- 3.3. Technological Advancements
- 3.4. Pricing Model Analysis
- 3.5. Clinical Trials Volume Analysis, 2023
- 3.5.1. Total Number of Clinical Trials, by Region (2023)
- 3.5.2. Total Number of Clinical Trials, by Phase (2023)
- 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
- 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
- 3.6. Sterile Injectables CDMO Market: Analysis Tools
- 3.6.1. Porter’s Five Forces Analysis
- 3.6.2. PESTEL Analysis
- 3.7. COVID-19 Impact Analysis
- Chapter 4. Sterile Injectables CDMO Market: Molecule Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Sterile Injectables CDMO Market Movement Analysis
- 4.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
- 4.4. Small Molecule
- 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 4.5. Large Molecule
- 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 5. Sterile Injectables CDMO Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Sterile Injectables CDMO Market Movement Analysis
- 5.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 5.4. Sterile Liquid Injectables
- 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 5.5. Pre-filled Syringes
- 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 5.6. Vials and Ampoules
- 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 6. Sterile Injectables CDMO Market: Service Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Sterile Injectables CDMO Market Movement Analysis
- 6.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
- 6.4. Contract Development
- 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 6.5. Contract Manufacturing
- 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 6.6. Packaging
- 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 6.7. Quality Control and Assurance
- 6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 6.8. Lyophilization Services
- 6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 7. Sterile Injectables CDMO Market: Therapeutic Area Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Sterile Injectables CDMO Market Movement Analysis
- 7.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Therapeutic Area, 2018 to 2030 (USD Million)
- 7.4. Oncology
- 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.5. Cardiovascular Diseases
- 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.6. Legal Representation
- 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.7. Central Nervous System Diseases
- 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.8. Infectious Disorders
- 7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.9. Musculoskeletal Diseases
- 7.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.10. Hormonal Diseases
- 7.10.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 7.11. Others
- 7.11.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 8. Sterile Injectables CDMO Market: Route of Administration Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Sterile Injectables CDMO Market Movement Analysis
- 8.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Route of Administration, 2018 to 2030 (USD Million)
- 8.4. Subcutaneous (SC)
- 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 8.5. Intravenous (IV)
- 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 8.6. Intramuscular (IM)
- 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 8.7. Others
- 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 9. Sterile Injectables CDMO Market: Modality by End Use Estimates & Trend Analysis
- 9.1. Segment Dashboard
- 9.2. Global Sterile Injectables CDMO Market Movement Analysis
- 9.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, End Use, 2018 to 2030 (USD Million)
- 9.4. Pharmaceutical Companies
- 9.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.5. Biopharmaceutical Companies
- 9.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.6. Others
- 9.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 10. Sterile Injectables CDMO Market: Regional Estimates & Trend Analysis
- 10.1. Regional Market Dashboard
- 10.2. Global Regional Market Snapshot
- 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 10.4. North America
- 10.4.1. North America Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.4.2. U.S.
- 10.4.2.1. Key Country Dynamics
- 10.4.2.2. Competitive Scenario
- 10.4.2.3. Regulatory Scenario
- 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.4.3. Canada
- 10.4.3.1. Key Country Dynamics
- 10.4.3.2. Competitive Scenario
- 10.4.3.3. Regulatory Scenario
- 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.4.4. Mexico
- 10.4.4.1. Key Country Dynamics
- 10.4.4.2. Competitive Scenario
- 10.4.4.3. Regulatory Scenario
- 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5. Europe
- 10.5.1. Europe Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.2. UK
- 10.5.2.1. Key Country Dynamics
- 10.5.2.2. Competitive Scenario
- 10.5.2.3. Regulatory Scenario
- 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.3. Germany
- 10.5.3.1. Key Country Dynamics
- 10.5.3.2. Competitive Scenario
- 10.5.3.3. Regulatory Scenario
- 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.4. France
- 10.5.4.1. Key Country Dynamics
- 10.5.4.2. Competitive Scenario
- 10.5.4.3. Regulatory Scenario
- 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.5. Italy
- 10.5.5.1. Key Country Dynamics
- 10.5.5.2. Competitive Scenario
- 10.5.5.3. Regulatory Scenario
- 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.6. Spain
- 10.5.6.1. Key Country Dynamics
- 10.5.6.2. Competitive Scenario
- 10.5.6.3. Regulatory Scenario
- 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.7. Denmark
- 10.5.7.1. Key Country Dynamics
- 10.5.7.2. Competitive Scenario
- 10.5.7.3. Regulatory Scenario
- 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.8. Sweden
- 10.5.8.1. Key Country Dynamics
- 10.5.8.2. Competitive Scenario
- 10.5.8.3. Regulatory Scenario
- 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.9. Norway
- 10.5.9.1. Key Country Dynamics
- 10.5.9.2. Competitive Scenario
- 10.5.9.3. Regulatory Scenario
- 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6. Asia Pacific
- 10.6.1. Asia Pacific Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6.2. China
- 10.6.2.1. Key Country Dynamics
- 10.6.2.2. Competitive Scenario
- 10.6.2.3. Regulatory Scenario
- 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6.3. Japan
- 10.6.3.1. Key Country Dynamics
- 10.6.3.2. Competitive Scenario
- 10.6.3.3. Regulatory Scenario
- 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6.4. India
- 10.6.4.1. Key Country Dynamics
- 10.6.4.2. Competitive Scenario
- 10.6.4.3. Regulatory Scenario
- 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6.5. Australia
- 10.6.5.1. Key Country Dynamics
- 10.6.5.2. Competitive Scenario
- 10.6.5.3. Regulatory Scenario
- 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6.6. South Korea
- 10.6.6.1. Key Country Dynamics
- 10.6.6.2. Competitive Scenario
- 10.6.6.3. Regulatory Scenario
- 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6.7. Thailand
- 10.6.7.1. Key Country Dynamics
- 10.6.7.2. Competitive Scenario
- 10.6.7.3. Regulatory Scenario
- 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.7. Latin America
- 10.7.1. Latin America Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.7.2. Brazil
- 10.7.2.1. Key Country Dynamics
- 10.7.2.2. Competitive Scenario
- 10.7.2.3. Regulatory Scenario
- 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.7.3. Argentina
- 10.7.3.1. Key Country Dynamics
- 10.7.3.2. Competitive Scenario
- 10.7.3.3. Regulatory Scenario
- 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.8. MEA
- 10.8.1. MEA Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.8.2. South Africa
- 10.8.2.1. Key Country Dynamics
- 10.8.2.2. Competitive Scenario
- 10.8.2.3. Regulatory Scenario
- 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.8.3. Saudi Arabia
- 10.8.3.1. Key Country Dynamics
- 10.8.3.2. Competitive Scenario
- 10.8.3.3. Regulatory Scenario
- 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.8.4. UAE
- 10.8.4.1. Key Country Dynamics
- 10.8.4.2. Competitive Scenario
- 10.8.4.3. Regulatory Scenario
- 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.8.5. Kuwait
- 10.8.5.1. Key Country Dynamics
- 10.8.5.2. Competitive Scenario
- 10.8.5.3. Regulatory Scenario
- 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- Chapter 11. Competitive Landscape
- 11.1. Market Participant Categorization
- 11.1.1. Market Leaders
- 11.1.2. Emerging Players
- 11.2. Service Heat Map Analysis (a comparative analysis of the players together)
- 11.3. Company Profiles
- 11.3.1. Boehringer Ingelheim GmbH
- 11.3.1.1. Company Overview
- 11.3.1.2. Financial Performance
- 11.3.1.3. Service Benchmarking
- 11.3.1.4. Strategic Initiatives
- 11.3.2. Boehringer Ingelheim GmbH
- 11.3.2.1. Company Overview
- 11.3.2.2. Financial Performance
- 11.3.2.3. Service Benchmarking
- 11.3.2.4. Strategic Initiatives
- 11.3.3. Vetter Pharma
- 11.3.3.1. Company Overview
- 11.3.3.2. Financial Performance
- 11.3.3.3. Service Benchmarking
- 11.3.3.4. Strategic Initiatives
- 11.3.4. Recipharm AB
- 11.3.4.1. Company Overview
- 11.3.4.2. Financial Performance
- 11.3.4.3. Service Benchmarking
- 11.3.4.4. Strategic Initiatives
- 11.3.5. Aenova Group
- 11.3.5.1. Company Overview
- 11.3.5.2. Financial Performance
- 11.3.5.3. Service Benchmarking
- 11.3.5.4. Strategic Initiatives
- 11.3.6. Fresenius Kabi
- 11.3.6.1. Company Overview
- 11.3.6.2. Financial Performance
- 11.3.6.3. Service Benchmarking
- 11.3.6.4. Strategic Initiatives
- 11.3.7. Famar
- 11.3.7.1. Company Overview
- 11.3.7.2. Financial Performance
- 11.3.7.3. Service Benchmarking
- 11.3.7.4. Strategic Initiatives
- 11.3.8. NextPharma Technologies
- 11.3.8.1. Company Overview
- 11.3.8.2. Financial Performance
- 11.3.8.3. Service Benchmarking
- 11.3.8.4. Strategic Initiatives
- 11.3.9. Ajinomoto Bio-Pharma Services
- 11.3.9.1. Company Overview
- 11.3.9.2. Financial Performance
- 11.3.9.3. Service Benchmarking
- 11.3.9.4. Strategic Initiatives
- 11.3.10. PCI Pharma Services
- 11.3.10.1. Company Overview
- 11.3.10.2. Financial Performance
- 11.3.10.3. Service Benchmarking
- 11.3.10.4. Strategic Initiatives
- 11.3.11. IDT Biologika
- 11.3.11.1. Company Overview
- 11.3.11.2. Financial Performance
- 11.3.11.3. Service Benchmarking
- 11.3.11.4. Strategic Initiatives
- 11.3.12. Alcami Corporation
- 11.3.12.1. Company Overview
- 11.3.12.2. Financial Performance
- 11.3.12.3. Service Benchmarking
- 11.3.12.4. Strategic Initiatives
- 11.3.13. Fareva Group
- 11.3.13.1. Company Overview
- 11.3.13.2. Financial Performance
- 11.3.13.3. Service Benchmarking
- 11.3.13.4. Strategic Initiatives
- 11.3.14. Eurofins CDMO
- 11.3.14.1. Company Overview
- 11.3.14.2. Financial Performance
- 11.3.14.3. Service Benchmarking
- 11.3.14.4. Strategic Initiatives
- 11.3.15. Siegfried Holding AG
- 11.3.15.1. Company Overview
- 11.3.15.2. Financial Performance
- 11.3.15.3. Service Benchmarking
- 11.3.15.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook